MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Centre Francois Baclesse104 enrolled

Overview

This study concerns elderly patients with cancer with onco-geriatric assessment. This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

SINGLE

Enrollment

104

Conditions

Neoplasms

Interventions

Passation of neuropsychological testOTHER

Passation of MoCA and MMS tests associated with neuropsychological test

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient aged over 70 years * Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study. * Patient candidate for oncogeriatric assessment * Patient agree to participate in the study * Using the French language Exclusion Criteria: * Primary central nervous system or cerebral metastasis * Evolutionary psychiatric pathology known (e.g. schizophrenia) * Severe Visual and / or Auditory Impairment * Patients unable to respond to cognitive tests * Patient (s) deprived of liberty, under guardianship or curatorship * Refusal of participation

Locations (6)

Centre François Baclesse

Caen, France

CHU

Caen, France

Cherbourg, France

Ch Compiegne

Compiègne, France

Centre Henri Becquerel

Rouen, France

Outcomes

Primary Outcomes

Evaluate the sensitivity of MoCA test

MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%

Time frame: Up 2 months after inclusion, before initiation of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.